ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Bosutinib was approved by the FDA for the treatment of CML in 2012 because of its ability to inhibit the BCR/ABL fusion gene product and its anticancer effects, which have been observed in imatinib-resistant CML [214].